Radiolabelled Peptides for Positron Emission Tomography and Endoradiotherapy in Oncology †

This review deals with the development of peptide-based radiopharmaceuticals for the use with positron emission tomography and peptide receptor radiotherapy. It discusses the pros and cons of this class of radiopharmaceuticals as well as the different labelling strategies, and summarises approaches...

Descripción completa

Detalles Bibliográficos
Autores principales: Rangger, Christine, Haubner, Roland
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7169460/
https://www.ncbi.nlm.nih.gov/pubmed/32019275
http://dx.doi.org/10.3390/ph13020022
_version_ 1783523793145167872
author Rangger, Christine
Haubner, Roland
author_facet Rangger, Christine
Haubner, Roland
author_sort Rangger, Christine
collection PubMed
description This review deals with the development of peptide-based radiopharmaceuticals for the use with positron emission tomography and peptide receptor radiotherapy. It discusses the pros and cons of this class of radiopharmaceuticals as well as the different labelling strategies, and summarises approaches to optimise metabolic stability. Additionally, it presents different target structures and addresses corresponding tracers, which are already used in clinical routine or are being investigated in clinical trials.
format Online
Article
Text
id pubmed-7169460
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-71694602020-04-22 Radiolabelled Peptides for Positron Emission Tomography and Endoradiotherapy in Oncology † Rangger, Christine Haubner, Roland Pharmaceuticals (Basel) Review This review deals with the development of peptide-based radiopharmaceuticals for the use with positron emission tomography and peptide receptor radiotherapy. It discusses the pros and cons of this class of radiopharmaceuticals as well as the different labelling strategies, and summarises approaches to optimise metabolic stability. Additionally, it presents different target structures and addresses corresponding tracers, which are already used in clinical routine or are being investigated in clinical trials. MDPI 2020-01-30 /pmc/articles/PMC7169460/ /pubmed/32019275 http://dx.doi.org/10.3390/ph13020022 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Rangger, Christine
Haubner, Roland
Radiolabelled Peptides for Positron Emission Tomography and Endoradiotherapy in Oncology †
title Radiolabelled Peptides for Positron Emission Tomography and Endoradiotherapy in Oncology †
title_full Radiolabelled Peptides for Positron Emission Tomography and Endoradiotherapy in Oncology †
title_fullStr Radiolabelled Peptides for Positron Emission Tomography and Endoradiotherapy in Oncology †
title_full_unstemmed Radiolabelled Peptides for Positron Emission Tomography and Endoradiotherapy in Oncology †
title_short Radiolabelled Peptides for Positron Emission Tomography and Endoradiotherapy in Oncology †
title_sort radiolabelled peptides for positron emission tomography and endoradiotherapy in oncology †
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7169460/
https://www.ncbi.nlm.nih.gov/pubmed/32019275
http://dx.doi.org/10.3390/ph13020022
work_keys_str_mv AT ranggerchristine radiolabelledpeptidesforpositronemissiontomographyandendoradiotherapyinoncology
AT haubnerroland radiolabelledpeptidesforpositronemissiontomographyandendoradiotherapyinoncology

Ejemplares similares